Yahoo
NSE - Delayed Quote INR

Neuland Laboratories Limited (NEULANDLAB.NS)

19,575.00 -125.00 (-0.63%)
At close: 3:29:50 PM GMT+5:30
NEULANDLAB.NS Q2 2027 earnings call
November 3, 2026 at 5 PM GMT+5:30
Chart Range Bar
Loading chart for NEULANDLAB.NS
  • Previous Close 19,700.00
  • Open 19,700.00
  • Bid --
  • Ask --
  • Day's Range 19,271.00 - 19,800.00
  • 52 Week Range 11,500.00 - 24,225.00
  • Volume 61,849
  • Avg. Volume 67,346
  • Market Cap (intraday) 251.145B
  • Beta (5Y Monthly) 0.34
  • PE Ratio (TTM) 50.45
  • EPS (TTM) 387.97
  • Earnings Date (est.) --
  • Forward Dividend & Yield 34.00 (0.17%)
  • Ex-Dividend Date Jul 24, 2026
  • 1y Target Est 24,678.50

Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

www.neulandlabs.com

2,183

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

NEULANDLAB.NS
29.23%
S&P BSE SENSEX (^BSESN)
11.33%

1-Year Return

NEULANDLAB.NS
19.05%
S&P BSE SENSEX (^BSESN)
9.97%

3-Year Return

NEULANDLAB.NS
406.85%
S&P BSE SENSEX (^BSESN)
17.93%

5-Year Return

NEULANDLAB.NS
1,094.90%
S&P BSE SENSEX (^BSESN)
25.89%

Earnings Trends

View More

Earnings Per Share (Normalized)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 6.42B
Earnings 1.48B
Profit Margin 23.02%

Q1

FY26

Q2

FY26

Q3

FY26

Q1

FY27

0
2B
4B
6B
5.0%
10.0%
15.0%
20.0%

Analyst Insights

View More

Analyst Price Targets

24,100.00
24,678.50 Average
19,575.00 Current
25,819.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    20.99%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    23.72B

  • Net Income Avi to Common (ttm)

    4.98B

  • Diluted EPS (ttm)

    387.97

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    766.7M

  • Total Debt/Equity (mrq)

    16.07%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: